Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947708 | 1.00 | CTSK (0.49) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL20273958 | 1.00 | CTSK (0.49) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL1543136 | 0.98 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL4157853 | 0.98 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL3208307 | 0.98 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL20438259 | 0.95 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL3545803 | 0.95 | CTSK (0.50) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL24065227 | 0.92 | CA1 (0.56) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL12794288 | 0.92 | CTSK (0.52) | CTSKBTKCA1CA2SIGMAR1 | |
| SCHEMBL12794285 | 0.92 | CTSK (0.52) | CTSKBTKCA1CA2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| WO-2007115933-A1 | THIAZOLYLDIHYDROINDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | CTSK 3859/4885BTK 3297/4885CA1 1675/4885 |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | CTSK 3859/4885BTK 3297/4885CA1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.